Stocks in Focus: Pingtan Marine Enterprise Ltd. (NASDAQ:PME), International Rectifier Corporation (NYSE:IRF), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Clovis Oncology (NASDAQ:CLVS), Endo International (NASDAQ:ENDP)

Pingtan Marine Enterprise Ltd. (NASDAQ:PME) announced that the Company has declared a cash dividend of $0.01 per share of common stock outstanding, payable in cash on or about February 18, 2015 to shareholders of record on January 22, 2015. This marks the second consecutive quarterly dividend paid by the Company, which it intends to continue paying on a quarterly basis. Pingtan Marine Enterprise Ltd. (NASDAQ:PME) belongs to Consumer Goods sector. Its net profit margin is 48.80% and weekly performance is 10.97%. On last trading day company shares ended up $2.63. Pingtan Marine Enterprise Ltd. (NASDAQ:PME) distance from 50-day simple moving average (SMA50) is 57.69%.

On Jan 07, International Rectifier Corporation (NYSE:IRF) announced that it expects closing of its pending merger with Infineon Technologies AG to occur on January 13, 2015. All necessary regulatory approvals for the transaction have been obtained. International Rectifier Corporation (NYSE:IRF) shares decreased -0.03% in last trading session and ended the day at $39.98. IRF Gross Margin is 36.70% and its return on assets is 4.90%. International Rectifier Corporation (NYSE:IRF) quarterly performance is 1.91%.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) outlined 2015 business priorities to support the development, approval and launch of new medicines that treat the underlying cause of cystic fibrosis (CF). The company also provided 2015 guidance for KALYDECO® (ivacaftor) net revenues and for non-GAAP operating expenses. At the start of 2014, more than 2,200 people with CF ages 6 and older with the G551D mutation were eligible for treatment with KALYDECO in North America, Europe and Australia. Following the expansion of the KALYDECO label throughout 2014, more than 3,100 people ages 6 and older are currently eligible for treatment with KALYDECO, including people with one of eight gating mutations and, in the United States, people with the R117H mutation. Vertex currently expects that by the end of 2015, more than 3,700 people may be eligible for treatment with KALYDECO, including children ages 2 to 5 and, in Europe, adults with the R117H mutation. On 13 January, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares moved up 1.94% and was closed at $120.60. VRTX EPS growth in last 5 year was 9.50%. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) year to date (YTD) performance is 1.52%.

Clovis Oncology, Inc. (NASDAQ:CLVS) announced that its Chief Executive Officer and President, Patrick J. Mahaffy, presented at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 1:30 PM Pacific Time. Clovis Oncology, Inc. (NASDAQ:CLVS) ended the last trading day at $61.34. Company weekly volatility is calculated as 5.47% and price to cash ratio as 4.03. Clovis Oncology, Inc. (NASDAQ:CLVS) showed a weekly performance of 9.97%.

Endo International P.L.C., said on Jan 09, that it is again changing executives below chief executive officer Rajiv De Silva. Endo said Don DeGolyer, the chief operating officer of the pharmaceuticals division “has decided to leave Endo to pursue other opportunities.” DeGolyer will step down effective March 1 and remain as an advisor until Aug. Endo International plc (NASDAQ:ENDP) shares moved up 2.45% in last trading session and ended the day at $79.87. ENDP Gross Margin is 54.70% and its return on assets is -15.80%. Endo International plc (NASDAQ:ENDP) quarterly performance is 30.51%.